TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Proportion of participants with new neuropsychological deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of complete histological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Radial Trabecular Volumetric Bone Mineral Density (Tr vBMD) at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change From Baseline in Radial Bone Strength (Failure Load) at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change From Baseline in Radial Bone Strength (Stiffness) at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Baseline in sciatic pain at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in sciatic pain at 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Direct Hospital Cost for patients included on waiting list for surgery due to disc herniation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Difference in fasting and/or post-prandial hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Use of reusable hot biopsy forceps
Endpoint domain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of patients achieving CR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in duration of days receiving mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC) From Time of Dose Extrapolated to Infinity (AUC[0-inf])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: failure rate of vacuum extraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: score change of The Panic Disorder Severity Scale (PDSS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in skin surface temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time to first Skeletal Related Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Microcirculation in septic shock patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: Objective improvement of voice parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 (liter)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FEV1 (%-percentage)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FVC (liter)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: systemic coagulation status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of Subjects Demonstrating ≥ 15 Letter Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anastomosis leakage
Endpoint domain: Adverse events/effects
Primary endpoint: Self-Report of Mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Basal metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diagnostic accuracy of biomarker for invasive aspergillosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Eating in the absence of hunger
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Pain Tolerance and Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Work performance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Individual Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pharmacokinetics of HU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular Hospitalizations or Cardiovascular Death
Endpoint domain: Mortality/survival
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC) of MMX Mesalamine (5-ASA) at Steady State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of MMX Mesalamine (5-ASA) at Steady State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Body Clearance (CL) of MMX Mesalamine (5-ASA) at Steady State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Major Bleeding or Clinically Relevant Non-Major Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: number of cross-sections with thrombus area more than 10%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence and grading of chemotherapy induced alopecia
Endpoint domain: Adverse events/effects
Primary endpoint: Adequacy of Diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change in laboratory-measured HgbA1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of suicidal event
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Allograft Rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of Participants Developing Acute Hypoxemic Respiratory Failure
Endpoint domain: Mortality/survival
Primary endpoint: Average Neoadjuvant Response Index (NRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with MYSTEP-score grade 3 and grade 2 (toxicity of MSC infusion)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with occurrence of any severe adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Graft function after liver transplantation - Number of participants with abnormal liver tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnesium Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Early pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Widespread Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time onset of delirium superimposed dementia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Tumor blood volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Permeability-surface area product
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 18-FDG PET SUV values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and Severity of Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of Central Sleep Apnea Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Accuracy of Other Various Sleep Metrics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Predicted Height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in energy intake at lunch time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Height of mandible
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injection-Site Pain
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse Events of Clinical Interest
Endpoint domain: Adverse events/effects
Primary endpoint: H3N2 HAI Seroconversion
Endpoint domain: Physiological/clinical
Primary endpoint: Improvement in Dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients reaching target red blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction of virus in blood to undetectable levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Normalization of serum ALT and AST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: prevention of hepatitis B virus reinfection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Diagnosis of dementia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of concentration of D-Amino Acid Oxidase in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: hypoxia-related interruptions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat mass changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal sympathetic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Patient preference for corrective lens
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ability to detect known sites of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pharmacokinetics (PK) of 89Zr-DFO-huJ591 PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biodistribution of 89Zr-DFO-huJ591 PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma myeloperoxidase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Phase II dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minute ventilation volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rapid shallow breathing index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Intensity and duration of itch episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Stillbirth Rate
Endpoint domain: Mortality/survival
Primary endpoint: Arterial blood gas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug and metabolite concentrations in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Complete resolution of vocal fold granuloma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of Time From Extubation to Discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood levels of drug over 72 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laboratory test results over 72 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vital signs, ECG results over 72 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of suicide attempt
Endpoint domain: Adverse events/effects
Primary endpoint: Change in burden of caregivers
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Body function and structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Urine and Serum NTx and Serum CTx Within Normal Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With Anti-Meningococcal Serogroup C Antibody Titre ≥1:8 Dil
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Measure atypical moles and melanoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in scores on the Appraisals of Disability: Primary and Secondary Scale (ADAPSS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in scores on the Disability Management Self-Efficacy Scale - Short
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in scores on the Effective Consumer Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Baseline antioxidant capacity (ORAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Selected biomarkers of nutritional status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Wound/Ulcers Healed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Malignant Arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acute Lung Edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Anxiety levels measured by STAI Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Annual Change Rate in Total Plaque Volume (TPV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Markers of iron status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of Participant Completion of Pilot
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Participant Abstinence Success at 2 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant Abstinence Success at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall cancer-specific survival
Endpoint domain: Mortality/survival
Primary endpoint: LDL-C target goals achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline oral health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Tooth Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-ejection Period (PEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Photoplethysmography (PPG) Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Brain Blood Flow in the Anterior Cingulate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Stress Index for Parents of Adolescents (SIPA)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bourbon TMS test (core strength)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in SVRI to PVRI Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Renal and non-renal adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Brain glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in 5 times Sit-to-Stand (STS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Component migration-cup
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Periprosthetic bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and joint outcomes
Primary endpoint: Component migration-stem
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Area under the Curve (AUC) glucagon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximal intimal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Volume of the osteolytic lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prefrontal GABA Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of grade 3/4 neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postoperative pancreatic fistula (POPF)
Endpoint domain: Adverse events/effects
Primary endpoint: Ability to feel bitterness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic parameters (Total cholesterol, HDL, LDL, Triglycerides, glycemia)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PCR rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum level of IGG4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 124I-FIAU tracer uptake in tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profiles of tramadol and acetaminophen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peeling without staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: anti-inflammatory activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cellular and humoral T-helper cells activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: endocrine-metabolic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Relative efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in N-back Task Performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Lesion Clearance Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Grade 3 unsolicited adverse events related to vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of solicited reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Clinician Rating on the Pediatric Anxiety Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PTSD Intensity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Difference in Acupuncture Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death or major stroke
Endpoint domain: Mortality/survival
Primary endpoint: Major ipsilateral stroke, neurological death, or rebleeding from the target aneurysm
Endpoint domain: Mortality/survival
Primary endpoint: Adequate angiographic occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Women With Vaginal Deliveries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: detection of atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Common femoral nerve damage
Endpoint domain: Adverse events/effects
Primary endpoint: Bleeding from femoral artery laceration
Endpoint domain: Adverse events/effects
Primary endpoint: Endomyometritis after delivery
Endpoint domain: Adverse events/effects
Primary endpoint: Blood As and Se concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary As and Se concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal As and Se concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chest Dysphoria
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Vdss elimination half life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure (office and 24-hour blood pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response to adenosine infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Flow mediated dilation of renal artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the American Board of Orthodontics - Objective Grading System (ABO-OGS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Content analysis from recorded interviews
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants with treatment emergent adverse events and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with clinically significant changes from baseline in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with clinically significant changes from baseline in physical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference of Maximum handgrip force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference of Maximum Electromiographic Activation Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombosis progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Bleeding complications of the UTEs
Endpoint domain: Adverse events/effects